Physician profile
Kimberly Jackson
NPI 1447536370
$12,819.37
in general payments reported to CMS, 2019-2025
38 companies · $2,582 in 2025
The $2,582 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $509 · 2021: $1,395 · 2022: $765 · 2023: $1,091 · 2024: $5,604 · 2025: $2,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,874 · Consulting Fee: $2,136 · Travel and Lodging: $1,167 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,874.21 |
| Consulting Fee | $2,136.00 |
| Travel and Lodging | $1,167.26 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,108.37 | 2023-2025 | Krystexxa, Evenity, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,394.98 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,240.96 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $686.39 | 2019-2025 | Bexsero, Arexvy, Shingrix |
| Abbvie INC. | $631.10 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $622.57 | 2019-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $496.49 | 2019-2023 | Xarelto |
| Pfizer INC. | $469.00 | 2019-2025 | |
| Lilly USA, LLC | $374.81 | 2019-2025 | Mounjaro, Zepbound |
| Horizon Therapeutics Plc | $345.48 | 2020-2023 | Krystexxa |
| Astellas Pharma US INC | $299.99 | 2021-2025 | Veozah |
| Amarin Pharma, INC. | $259.68 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $222.16 | 2023-2025 | Rexulti |
| Corcept Therapeutics | $208.29 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $168.47 | 2019-2025 | Capvaxive, Verquvo |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $150.40 | 2022-2025 | |
| Lundbeck LLC | $147.66 | 2023-2025 | Rexulti, Vyepti |
| Abbott Laboratories | $138.87 | 2021-2025 | Freestyle Libre 3 |
| Organogenesis INC. | $121.97 | 2022 | |
| Madrigal Pharmaceuticals | $91.37 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $86.05 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sunovion Pharmaceuticals INC. | $78.41 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $73.78 | 2024-2025 | Camzyos, Eliquis |
| Allergan, INC. | $61.31 | 2019-2020 | |
| Dexcom, INC. | $56.36 | 2024-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $54.30 | 2024-2025 | Gemtesa |
| Ironshore Pharmaceuticals INC. | $46.51 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $27.41 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $19.15 | 2021 | |
| Solventum Corporation | $19.00 | 2025 | Activ.A.C. |
| Biohaven Pharmaceuticals, INC. | $17.45 | 2021 | |
| Phadia US INC. | $16.40 | 2024 | Immunocap |
| Boston Scientific Corporation | $16.21 | 2025 | Ams 700 |
| Daiichi Sankyo INC. | $16.19 | 2020 | |
| Avanir Pharmaceuticals, INC. | $15.18 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.15 | 2022 | |
| Biogen, INC. | $11.31 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.